HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Evidence Needed For Hair Volume’s Baldness-Reversing Claims – NAD

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division advises New Nordic USA to discontinue claims suggesting that its Hair Volume dietary supplement strengthens hair and even reverses genetic pattern baldness in women. The bulk of the advertiser’s submitted evidence was either insufficient or irrelevant to the claims in question.

You may also be interested in...



Firm's Discontinued Hair Volume Claims Keep Growing Back; NAD Alerts FTC

New Nordic's seeming refusal to dispense with hair-growth claims in ads for its Hair Volume supplement, despite repeated promises to the National Advertising Division, has resulted in a referral to the Federal Trade Commission.

Firm's Discontinued Hair Volume Claims Keep Growing Back; NAD Alerts FTC

New Nordic's seeming refusal to dispense with hair-growth claims in ads for its Hair Volume supplement, despite repeated promises to the National Advertising Division, has resulted in a referral to the Federal Trade Commission.

Firm's Discontinued Hair Volume Claims Keep Growing Back; NAD Alerts FTC

New Nordic's seeming refusal to dispense with hair-growth claims in ads for its Hair Volume supplement, despite repeated promises to the National Advertising Division, has resulted in a referral to the Federal Trade Commission.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel